Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.

Biotechnology

Adverum Biotech

Laurent Fischer

Senior Director, Global Commerical Strategy

Joanna D.

Adam Turpcu

Rabia Gurses Ozden

Romuald Corbau

R. Andrew Ramelmeier

Bill Tan

Linda Rubinstein

Star Seyedkazemi

Dena House

John Rakow

Heikki Jouttijärvi

Kishor Peter Soparkar

Carla Fiankan

The Scientific Team at Adverum Biotechnologies conducts cutting-edge research and development to advance gene therapy treatments for ocular and rare diseases. They design, evaluate, and optimize therapeutic candidates like ADVM-022 through rigorous scientific analysis and clinical studies. The team also collaborates with medical and technological experts to ensure the efficacy and safety of innovative treatments for conditions such as wet age-related macular degeneration.

Scientific Team

Corporate Affairs

Leadership Team

Scientific Team

About

Team members

Other teams at Adverum Biotech

Corporate Affairs

Leadership Team